Tuberculosis Vaccine Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Immune Vaccine and Therapy Vaccine), By Application (Self-Procurement, UNICEF and Other) and Regional Insights and Forecast to 2031

Updated On: 06 May 2024

TUBERCULOSIS VACCINE TREATMENT MARKET REPORT OVERVIEW

• 

• to learn more about this report

The global tuberculosis vaccine treatment market size was USD 72 million in 2020 and will touch USD 87 million by 2027, exhibiting a CAGR of 2.9% during the forecast period.

The primary vaccine for tuberculosis (TB) is Bacillus Calmette-Guérin (BCG). BCG is a live attenuated strain of Mycobacterium bovis, a bacterium related to the Mycobacterium tuberculosis bacteria that cause TB in humans. BCG is used as a preventive measure against severe forms of tuberculosis, particularly in infants and young children. The BCG vaccine does not provide complete immunity against tuberculosis vaccine treatment, but it can help protect against severe forms of the disease, such as TB meningitis and miliary TB, in young children. It is not as effective in preventing pulmonary TB, which is the most common form of the disease in adults. It's important to note that BCG vaccination policies vary by country, and not all countries include it as part of their routine vaccination schedules. In some places, BCG vaccination is recommended for specific groups at higher risk of TB exposure or severe TB disease.

In addition to vaccination, the treatment of active tuberculosis involves a combination of antibiotics taken over several months. This treatment aims to kill the bacteria causing the infection and prevent the development of drug-resistant strains. Commonly used anti-TB medications include isoniazid, rifampin, ethambutol, and pyrazinamide. TB treatment usually requires a multidrug approach, and the exact combination of drugs and the duration of treatment depend on factors such as the type of TB, drug susceptibility of the bacteria, and the patient's overall health. It is essential for individuals diagnosed with TB to complete the full course of treatment as prescribed by healthcare professionals to ensure the best possible outcome and reduce the risk of relapse or the development of drug-resistant strains.

COVID-19 Impact: Impact on TB Diagnosis and Treatment Hindered Market Growth Amid Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic has led to disruptions in healthcare services worldwide, with a focus on managing and treating COVID-19 cases. This shift in priorities may have affected routine vaccination programs, including those for tuberculosis. The attention and resources directed towards managing the pandemic may have impacted the diagnosis and treatment of tuberculosis. Delays in testing, diagnosis, and treatment initiation could potentially affect TB outcomes. The pandemic has driven significant global attention and resources towards vaccine research and development, including efforts to develop vaccines against COVID-19. This increased focus on vaccines might indirectly influence funding and attention available for tuberculosis vaccine research. The global supply chain disruptions caused by the pandemic could have affected the availability and distribution of tuberculosis vaccines and medications. This might impact the ability of healthcare systems to procure and administer these products.

LATEST TRENDS

"Focus on Latent TB Infection (LTBI) and Drug Development to Drive Market Growth"

There has been ongoing research into developing new and more effective tuberculosis vaccines. Scientists and researchers are exploring different vaccine candidates and strategies to enhance protection against TB, especially in populations where the current Bacillus Calmette-Guérin (BCG) vaccine may have limitations. There is a growing emphasis on addressing latent TB infection, where individuals have TB bacteria in their bodies but do not show symptoms. Research is underway to develop drugs and vaccines that can prevent latent TB from progressing to active TB disease. International organizations, governments, and nonprofits are increasingly collaborating to address the global burden of TB. Funding initiatives and partnerships aim to accelerate research, development, and access to TB vaccines and treatments, particularly in high-burden regions.

TUBERCULOSIS VACCINE TREATMENT MARKET SEGMENTATION

• 

• to learn more about this report

• By Type

Based on type the global market can be categorized into immune vaccine and therapy vaccine.

Preventive vaccines are designed to prevent infections. They stimulate the immune system to recognize and remember specific pathogens, such as viruses or bacteria, so that if the person is later exposed to the actual pathogen, their immune system can mount a rapid and effective response. Therapeutic vaccines, also known as treatment or cancer vaccines, are a type of immunotherapy designed to treat existing diseases, typically cancers or chronic infections, rather than preventing them.

• By Application

Based on application the global market can be categorized into self-procurement, UNICEF and other.

Self-procurement typically refers to the process by which an organization or entity procures goods or services directly, without involving external intermediaries or agencies. In the context of vaccines, it could refer to a country or organization directly purchasing vaccines from manufacturers or suppliers. UNICEF was established on December 11, 1946, by the United Nations General Assembly to provide emergency food and healthcare to children and mothers in countries that were devastated by World War II. Over time, its mission expanded to address the long-term needs of children and mothers globally.

DRIVING FACTORS

"Emergence of Drug-Resistant Strains to Augment the Market"

The significant burden of TB worldwide, with millions of new cases each year, is a primary driving factor. TB remains a major public health concern, especially in regions with high prevalence rates. The emergence of drug-resistant strains of Mycobacterium tuberculosis, the bacterium causing TB, highlights the need for alternative and more effective treatment options, including vaccines contributes to tuberculosis vaccine treatment market growth. Drug-resistant TB poses a significant challenge to traditional antibiotic treatments. International commitments and strategies, such as those outlined by the World Health Organization (WHO) and the Stop TB Partnership, drive research and development efforts for new TB vaccines. These commitments aim to achieve global targets for reducing TB incidence and mortality.

"Public-Private Partnerships to Expand the Market"

TB often coexists with other infectious diseases, such as HIV. Co-infections can complicate treatment regimens and worsen outcomes. Addressing TB through vaccines becomes crucial in managing its impact in populations with a high prevalence of co-infections. Advances in vaccine development technologies and research methodologies contribute to the exploration of new and improved TB vaccines. Innovations in immunology and molecular biology have expanded our understanding of the immune response to TB infection, aiding in vaccine design. Collaborations between public and private sectors, as well as academic institutions, pharmaceutical companies, and non-profit organizations, play a vital role. These partnerships can leverage resources, expertise, and funding to accelerate TB vaccine development and distribution.

RESTRAINING FACTOR

"Lack of an Ideal Animal Model to Potentially Impede Market Growth"

TB is a complex disease with various factors influencing its transmission, progression, and treatment. The ability of Mycobacterium tuberculosis to evade the immune system and establish latent infections makes the development of effective vaccines challenging. The absence of a reliable animal model that accurately recapitulates human TB infection and disease progression hinders preclinical testing of vaccine candidates. This complicates the assessment of vaccine efficacy and safety before moving to human trials. Developing an effective TB vaccine has proven difficult due to the unique characteristics of the bacterium and the complex host immune response. The lack of well-defined immune correlates of protection further complicates the evaluation of vaccine candidates.

TUBERCULOSIS VACCINE TREATMENT MARKET REGIONAL INSIGHTS

• 

• to learn more about this report

"Europe to Dominate the Market due to Prevalence of HIV Co-Infection"

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East &Africa.

Several European countries and institutions are actively engaged in tuberculosis vaccine treatment market share. Organizations such as the European & Developing Countries Clinical Trials Partnership (EDCTP) support collaborative efforts between European and African researchers. The United States and Canada are significant contributors to TB research and development. Institutions like the National Institutes of Health (NIH) in the U.S. have been involved in funding and conducting TB vaccine trials. Europe has been a focal point for TB research and vaccine development, given its high burden of TB and the prevalence of HIV co-infection. Collaborative efforts between South African and international researchers are notable.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Innovation and Market Expansion"

The market is significantly influenced by key industry players that play a pivotal role in driving market dynamics and shaping consumer preferences. These key players possess extensive retail networks and online platforms, providing consumers with easy access to a wide variety of wardrobe options. Their strong global presence and brand recognition have contributed to increased consumer trust and loyalty, driving product adoption. Moreover, these industry giants continually invest in research and development, introducing innovative designs, materials, and smart features, catering to evolving consumer needs and preferences. The collective efforts of these major players significantly impact the competitive landscape and future trajectory of the market.

List of Market Players Profiled

• Merck (U.S.)
• Serum Institute of India (India)
• AJ Vaccines (Denmark)
• BioFarma (Indonesia)

INDUSTRIAL DEVELOPMENT

March, 2020: The industrial development of the tuberculosis (TB) vaccine treatment market involves various stages, including research and development, clinical trials, manufacturing, regulatory approval, and distribution. Research begins with identifying potential vaccine targets, understanding the biology of Mycobacterium tuberculosis, and determining the immune responses needed for protection.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.